Assignee
AICURIS ANTI INFECTIVE CURES GMBH
DE·11 granted patents·4 pending applications·27 citations·filing 2014–2024
Top patents by PatentIndex Score
15 records- 0192US10137117B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Nov 27, 2018·6 cites·22 claims
- 0292US9592225B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI-INFECTIVE CURES GMBH·Filed 2015·Granted Mar 14, 2017·8 cites·22 claims
- 0391US9889124B2Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2015·Granted Feb 13, 2018·6 cites·30 claims
- 0488US11021474B2N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereofAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Jun 1, 2021·4 cites·11 claims
- 0583US11266636B2Maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes virusesAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Mar 8, 2022·2 cites·15 claims
- 0678US2025042893A1N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereofAICURIS ANTI INFECTIVE CURES GMBH·Filed 2024·Application pending·0 cites
- 0772USRE49697ECrystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulationsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2020·Granted Oct 17, 2023·0 cites·32 claims
- 0870US12152022B2N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereofAICURIS ANTI INFECTIVE CURES GMBH·Filed 2021·Granted Nov 26, 2024·0 cites·24 claims
- 0970USRE49698ESubstituted dihydroquinazolinesAICURIS ANTI INFECTIVE CURES GMBH·Filed 2020·Granted Oct 17, 2023·0 cites·27 claims
- 1069US10442773B2Amorphous letermovir and solid pharmaceutical formulations thereof for oral administrationAICURIS ANTI INFECTIVE CURES GMBH·Filed 2014·Granted Oct 15, 2019·1 cites·18 claims
- 1154US11213516B2Intravaginally applicable devices comprising antiviral compoundsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2018·Granted Jan 4, 2022·0 cites·19 claims
- 1250US2021380664A1Hcmv entry inhibitorsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2021·Application pending·0 cites
- 1348US11390661B2HCMV entry inhibitorsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Granted Jul 19, 2022·0 cites·9 claims
- 1437US2019328716A1Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infectionsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Application pending·0 cites
- 1537US2019365720A1Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositionsAICURIS ANTI INFECTIVE CURES GMBH·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when AICURIS ANTI INFECTIVE CURES GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →